{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T04:37:43Z","timestamp":1794890263718,"version":"4.9.1"},"reference-count":58,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,27]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>High-dose posttransplantation cyclophosphamide (HD-PTCy), given at 50 mg\/kg\/day on days +3\/+4, is a standard-of-care graft-versus-host disease (GVHD) prophylaxis for allogeneic hematopoietic cell transplantation (HCT). Our murine MHC\u2013haploidentical HCT studies suggested intermediate-dose PTCy produces superior GVHD control compared with HD-PTCy and PTCy is maximally effective on day +4. We conducted a single-institutional prospective phase 1\/2 trial to reduce PTCy dosing to 25 mg\/kg\/day on days +3\/+4 or on day +4 only for myeloablative HLA\u2013haploidentical bone marrow HCT using PTCy, sirolimus, and mycophenolate mofetil. Among 35 patients, 89% were ethnic\/racial minorities, 46% had high\/very-high-risk disease, and median comorbidity score was 3. The phase 1 dose-limiting-toxicity, grade III-IV acute GVHD, was not observed after either reduced-PTCy dose level. PTCy 25 mg\/kg\/day on days +3\/+4 (intermediate-dose (ID)-PTCy; n = 23), the phase 2 dose, resulted in no grade II-IV acute GVHD; 2-year cumulative incidences of chronic GVHD requiring systemic immunosuppression, nonrelapse mortality, and relapse were 13%, 17%, and 22%, and 2-year overall survival, disease-free survival, and GVHD-free\/relapse-free survival were 61%, 61%, and 52%. In exploratory analysis compared with HD-PTCy (n = 5), ID-PTCy resulted in significantly faster engraftment and T-cell reconstitution, fewer transfusions, less mucositis, and reduced severity of BK-virus\u2013associated cystitis\/urethritis; area-under-the-curve exposure of 4-hydroxycyclophosphamide (4HCY), a key cyclophosphamide metabolite, correlated with these outcomes but not with chronic GVHD occurrence. Ideal-body-weight\u2013based PTCy dosing best approximated 4HCY exposure. ID-PTCy is effective and has apparent clinical benefits compared with HD-PTCy. Before broader implementation, further studies are needed to confirm these findings and define optimal PTCy dosing across various donor\/graft types. This trial was registered at www.clinicaltrials.gov as #NCT03983850.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014879","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T17:02:36Z","timestamp":1738774956000},"page":"2553-2569","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":41,"title":["Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7597-2646","authenticated-orcid":false,"given":"Mustafa A.","family":"Hyder","sequence":"first","affiliation":[{"name":"1Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4868-6852","authenticated-orcid":false,"given":"Dimana","family":"Dimitrova","sequence":"additional","affiliation":[{"name":"1Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby","family":"Sabina","sequence":"additional","affiliation":[{"name":"1Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"DeVries","sequence":"additional","affiliation":[{"name":"1Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannine S.","family":"McCune","sequence":"additional","affiliation":[{"name":"2Department of Hematologic Malignancies, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith J.","family":"McAdams","sequence":"additional","affiliation":[{"name":"1Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis A.","family":"Flomerfelt","sequence":"additional","affiliation":[{"name":"3Clinical Research Correlatives Core, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christi","family":"McKeown","sequence":"additional","affiliation":[{"name":"1Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Sadler","sequence":"additional","affiliation":[{"name":"1Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Chai","sequence":"additional","affiliation":[{"name":"1Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Hughes","sequence":"additional","affiliation":[{"name":"4Clinical Center Pharmacy Department, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Napier","sequence":"additional","affiliation":[{"name":"1Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Stokes","sequence":"additional","affiliation":[{"name":"1Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Sponaugle","sequence":"additional","affiliation":[{"name":"1Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil","family":"Rechache","sequence":"additional","affiliation":[{"name":"1Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Parta","sequence":"additional","affiliation":[{"name":"5Clinical Research Directorate\/Clinical Monitoring Research Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Cuellar-Rodriguez","sequence":"additional","affiliation":[{"name":"6National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Figg","sequence":"additional","affiliation":[{"name":"7Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyoyoung","family":"Choo-Wosoba","sequence":"additional","affiliation":[{"name":"8Biostatistics and Data Management Section, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth M.","family":"Steinberg","sequence":"additional","affiliation":[{"name":"8Biostatistics and Data Management Section, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Kanakry","sequence":"additional","affiliation":[{"name":"1Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7736-2056","authenticated-orcid":false,"given":"Christopher G.","family":"Kanakry","sequence":"additional","affiliation":[{"name":"1Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"issue":"1","key":"2025052708521029700_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/nrclinonc.2015.128","article-title":"Modern approaches to HLA-haploidentical blood or marrow transplantation","volume":"13","author":"Kanakry","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"2025052708521029700_bib2","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.3389\/fimmu.2019.02668","article-title":"Mechanisms of graft-versus-host disease prevention by post-transplantation cyclophosphamide: an evolving understanding","volume":"10","author":"Nunes","year":"2019","journal-title":"Front Immunol"},{"issue":"6","key":"2025052708521029700_bib3","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2025052708521029700_bib4","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","article-title":"Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide","volume":"8","author":"O'Donnell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2025052708521029700_bib5","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1200\/JCO.1997.15.5.1767","article-title":"Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings","volume":"15","author":"Szydlo","year":"1997","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025052708521029700_bib6","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"2025052708521029700_bib7","doi-asserted-by":"crossref","first-page":"346.e1","DOI":"10.1016\/j.jtct.2023.03.007","article-title":"Real-world data showing trends and outcomes by race and ethnicity in allogeneic hematopoietic cell transplantation: a report from the Center for International Blood and Marrow Transplant Research","volume":"29","author":"Auletta","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"25","key":"2025052708521029700_bib8","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bolanos-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"2025052708521029700_bib9","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/bloodadvances.2021005847","article-title":"Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial","volume":"6","author":"Broers","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"2025052708521029700_bib10","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/JCO.21.02293","article-title":"Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies","volume":"40","author":"Luznik","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025052708521029700_bib11","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jaccao.2021.02.011","article-title":"Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation","volume":"3","author":"Dulery","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"1","key":"2025052708521029700_bib12","doi-asserted-by":"crossref","first-page":"e14364","DOI":"10.1111\/petr.14364","article-title":"Evaluation of the risk factors for BK virus-associated hemorrhagic cystitis in pediatric bone marrow transplantation patients: does post-transplantation cyclophosphamide increase the frequency?","volume":"27","author":"Ersoy","year":"2023","journal-title":"Pediatr Transplant"},{"issue":"23","key":"2025052708521029700_bib13","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1182\/blood.2020009362","article-title":"Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis","volume":"137","author":"Goldsmith","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2025052708521029700_bib14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41409-023-02131-z","article-title":"Post-transplantation cyclophosphamide is associated with increased bacterial infections","volume":"59","author":"Ustun","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2025052708521029700_bib15","doi-asserted-by":"crossref","first-page":"114.e1","DOI":"10.1016\/j.jtct.2023.09.017","article-title":"Incidence and impact of fungal infections in post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical hematopoietic cell transplantation: a Center for International Blood and Marrow Transplant Research analysis","volume":"30","author":"Papanicolaou","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"2025052708521029700_bib16","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.bbmt.2018.12.142","article-title":"Higher incidence of hemorrhagic cystitis following haploidentical related donor transplantation compared with matched related donor transplantation","volume":"25","author":"Copelan","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2025052708521029700_bib17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/bjh.17563","article-title":"Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation","volume":"194","author":"Mulroney","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"2025052708521029700_bib18","doi-asserted-by":"crossref","first-page":"48.e1","DOI":"10.1016\/j.jtct.2021.09.015","article-title":"Post-transplantation cyclophosphamide is associated with an increase in non-cytomegalovirus herpesvirus infections in patients with acute leukemia and myelodysplastic syndrome","volume":"28","author":"Singh","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"2025052708521029700_bib19","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.4049\/jimmunol.155.9.4179","article-title":"A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers","volume":"155","author":"Colson","year":"1995","journal-title":"J Immunol"},{"issue":"7","key":"2025052708521029700_bib20","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.4049\/jimmunol.157.7.2820","article-title":"Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach","volume":"157","author":"Colson","year":"1996","journal-title":"J Immunol"},{"issue":"12","key":"2025052708521029700_bib21","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood.V98.12.3456","article-title":"Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide","volume":"98","author":"Luznik","year":"2001","journal-title":"Blood"},{"issue":"7","key":"2025052708521029700_bib22","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-135-7-200110020-00006","article-title":"Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia","volume":"135","author":"Brodsky","year":"2001","journal-title":"Ann Intern Med"},{"issue":"3","key":"2025052708521029700_bib23","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood.2020007535","article-title":"Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial","volume":"137","author":"Fuchs","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2025052708521029700_bib24","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1172\/JCI124218","article-title":"Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression","volume":"129","author":"Wachsmuth","year":"2019","journal-title":"J Clin Invest"},{"issue":"2","key":"2025052708521029700_bib25","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.bbmt.2019.09.030","article-title":"Optimized timing of post-transplantation cyclophosphamide in MHC-haploidentical murine hematopoietic cell transplantation","volume":"26","author":"Wachsmuth","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025052708521029700_bib26","doi-asserted-by":"crossref","first-page":"796349","DOI":"10.3389\/fimmu.2022.796349","article-title":"Post-transplantation cyclophosphamide uniquely restrains alloreactive CD4(+) T-cell proliferation and differentiation after murine MHC-haploidentical hematopoietic cell transplantation","volume":"13","author":"Hadjis","year":"2022","journal-title":"Front Immunol"},{"issue":"211","key":"2025052708521029700_bib27","doi-asserted-by":"crossref","first-page":"211ra157","DOI":"10.1126\/scitranslmed.3006960","article-title":"Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide","volume":"5","author":"Kanakry","year":"2013","journal-title":"Sci Transl Med"},{"issue":"13","key":"2025052708521029700_bib28","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1182\/blood-2013-10-525873","article-title":"Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice","volume":"124","author":"Ganguly","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2025052708521029700_bib29","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2025052708521029700_bib30","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2025052708521029700_bib31","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","article-title":"Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation","volume":"125","author":"Holtan","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2025052708521029700_bib32","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jtct.2021.04.007","article-title":"Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the American Society for Transplantation and Cellular Therapy","volume":"27","author":"Kharfan-Dabaja","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"2025052708521029700_bib33","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/sj.bmt.1703015","article-title":"Engraftment syndrome following hematopoietic stem cell transplantation","volume":"27","author":"Spitzer","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"2025052708521029700_bib34","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2025052708521029700_bib35","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"6","key":"2025052708521029700_bib36","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/clpt.2009.27","article-title":"Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy","volume":"85","author":"McCune","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"2025052708521029700_bib37","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.1995.13.5.1103","article-title":"Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation","volume":"13","author":"Bedi","year":"1995","journal-title":"J Clin Oncol"},{"issue":"18","key":"2025052708521029700_bib38","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.20.03502","article-title":"National marrow donor program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide","volume":"39","author":"Shaw","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"2025052708521029700_bib39","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1182\/blood-2016-09-737825","article-title":"Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide","volume":"129","author":"Kanakry","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2025052708521029700_bib40","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/j.bbmt.2015.07.005","article-title":"Mixed T lymphocyte chimerism after allogeneic hematopoietic transplantation is predictive for relapse of acute myeloid leukemia and myelodysplastic syndromes","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"31","key":"2025052708521029700_bib41","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1200\/JCO.2013.54.0625","article-title":"Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning","volume":"32","author":"Kanakry","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025052708521029700_bib42","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jtct.2023.12.021","article-title":"Interim results of a phase I\/II trial of intermediate-dose post-transplantation cyclophosphamide after reduced intensity conditioned HLA-mismatched bone marrow transplantation for older or unfit patients","volume":"30","author":"McCurdy","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"2025052708521029700_bib43","doi-asserted-by":"crossref","first-page":"e1356152","DOI":"10.1080\/2162402X.2017.1356152","article-title":"Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF\/ATG induced GVHD protective activity and improve haploidentical transplant outcomes","volume":"6","author":"Wang","year":"2017","journal-title":"Oncoimmunology"},{"key":"2025052708521029700_bib44","doi-asserted-by":"crossref","first-page":"921293","DOI":"10.3389\/fimmu.2022.921293","article-title":"Modified combination of anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) as compared with standard ATG protocol in haploidentical peripheral blood stem cell transplantation for acute leukemia","volume":"13","author":"Barkhordar","year":"2022","journal-title":"Front Immunol"},{"issue":"11","key":"2025052708521029700_bib45","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/s41409-023-02085-2","article-title":"Reduced post-transplant cyclophosphamide dose with antithymocyte globulin in peripheral blood stem cell haploidentical transplantation","volume":"58","author":"Dulery","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"2025052708521029700_bib46","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.exphem.2015.07.006","article-title":"HLA haploidentical peripheral blood stem cell transplantation using reduced dose of posttransplantation cyclophosphamide for poor-prognosis or refractory leukemia and myelodysplastic syndrome","volume":"43","author":"Nakamae","year":"2015","journal-title":"Exp Hematol"},{"issue":"4","key":"2025052708521029700_bib47","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41409-022-01908-y","article-title":"Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies","volume":"58","author":"Dulery","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2025052708521029700_bib48","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/s41409-020-01065-0","article-title":"Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation","volume":"56","author":"Sugita","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2025052708521029700_bib49","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/bmt.2016.301","article-title":"Dose-adapted post-transplant cyclophosphamide for HLA-haploidentical transplantation in Fanconi anemia","volume":"52","author":"Thakar","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2025052708521029700_bib50","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1038\/s41409-021-01282-1","article-title":"T-cell replete haploidentical transplantation with reduced post-transplant cyclophosphamide in six children with infantile osteopetrosis","volume":"56","author":"Al-Seraihy","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2025052708521029700_bib51","doi-asserted-by":"crossref","first-page":"2313357","DOI":"10.1080\/16078454.2024.2313357","article-title":"More about post-transplant cyclophosphamide in haploidentical grafts: full or reduced doses?","volume":"29","author":"Gallardo-Perez","year":"2024","journal-title":"Hematology"},{"issue":"3","key":"2025052708521029700_bib52","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1182\/blood-2005-07-3032","article-title":"Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells","volume":"107","author":"Coenen","year":"2006","journal-title":"Blood"},{"issue":"4","key":"2025052708521029700_bib53","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1182\/bloodadvances.2016002766","article-title":"Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide","volume":"1","author":"Kasamon","year":"2017","journal-title":"Blood Adv"},{"issue":"1","key":"2025052708521029700_bib54","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbmt.2019.08.018","article-title":"Prospective study of a novel, radiation-Free, reduced-intensity bone marrow transplantation platform for primary immunodeficiency diseases","volume":"26","author":"Dimitrova","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2025052708521029700_bib55","doi-asserted-by":"crossref","first-page":"229.e1","DOI":"10.1016\/j.jtct.2023.11.010","article-title":"Sirolimus is an acceptable alternative to tacrolimus for graft-versus-host disease prophylaxis after haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide","volume":"30","author":"Elmariah","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"17","key":"2025052708521029700_bib56","doi-asserted-by":"crossref","first-page":"4994","DOI":"10.1182\/bloodadvances.2022006961","article-title":"Efflux capacity and aldehyde dehydrogenase both contribute to CD8+ T-cell resistance to posttransplant cyclophosphamide","volume":"6","author":"Patterson","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"2025052708521029700_bib57","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/00003088-200544110-00003","article-title":"Clinical pharmacokinetics of cyclophosphamide","volume":"44","author":"de Jonge","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"suppl 1","key":"2025052708521029700_bib58","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1182\/blood-2023-188032","article-title":"Large-scale post-transplant TCR deep sequencing reveals a major T cell diversity bottleneck with post-transplant cyclophosphamide with implications for both efficacy and toxicity: results of the BMT CTN 1801 study","volume":"142","author":"Kean","year":"2023","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/10\/2553\/2375082\/blooda_adv-2024-014879-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/10\/2553\/2375082\/blooda_adv-2024-014879-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T08:52:27Z","timestamp":1748335947000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/10\/2553\/535454\/Intermediate-dose-posttransplantation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,5,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014879","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5,27]]},"published":{"date-parts":[[2025,5,19]]}}}